Open Monoclonal Technology Announces OmniRat™ Collaboration With CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc.
PALO ALTO, Calif.--(BUSINESS WIRE)--
Open Monoclonal Technology, Inc. (OMT) today announced a discovery
collaboration with CNA Development LLC, an affiliate of Janssen
OMT will employ its OmniRat transgenic animal platform to generate
human antibodies with great specificity, affinity and manufacturability.
OmniRat enables developers to skip the need to humanize animal-derived
antibodies before initiating preclinical pharmacokinetic evaluations of
Dr. Roland Buelow, Founder and CEO of OMT, said: "OmniRat makes
antibodies with fully human idiotypes as well as normal rats make normal
rat antibodies. We look forward to making the technology available to
Janssen, one of the pioneers and leaders in therapeutic human
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic
engineering of animals for the development of human therapeutic
antibodies . OMT
has created , the first fully human monoclonal antibody
platform based on transgenic rats. OmniRat uses an improved
understanding of B cell development and a new approach to inactivation
of endogenous antibody expression, which enables them to make antibodies
with human idiotypes as efficiently as wild type rats make normal
antibodies. OmniRat represents a novel and proprietary technology with
unrestricted development options for fully human monoclonal antibodies,
available worldwide for all targets and indications. OMT also develops a
transgenic mouse, , to complement OmniRat and further
increase epitope coverage in human antibody development.
integrates OMTs transgenic animal platforms, proven protein and DNA
immunization, and Gel-Encapsulated Microenvironment (GEM) deep antibody
screening to enable fast and cost-efficient generation and
identification of preferred human therapeutic antibody candidates.
Open Monoclonal Technology, Inc.Brian Lundstrom, +email@example.com
Source: Open Monoclonal Technology, Inc.